Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Sekisui Diagnostics

Download Mobile App




Co-Receptor Tropism Assay Launched for HIV Patients

By HospiMedica staff writers
Posted on 29 Aug 2007
The human immunodeficiency virus (HIV) diagnostic co-receptor tropism assay has been launched for patients in the United States.

Called Trofile, the assay determines which co-receptor a patient's HIV strain or strains use for viral entry--CCR5, CXCR4, or a combination of CCR5 and CXCR4. More...
The cellular gateways that a particular HIV strain uses to gain entry into a healthy CD4+ cell is known as the patient's tropism.

Trofile amplifies a patient's HIV genome (from his/her blood sample) to make HIV particles specific to that individual patient. The resultant HIV particles are then used to infect CCR5- and CXCR4- expressing cell lines. Once the virus infects the cell and undergoes its single round of replication, a reporter gene expresses its indicator gene (luciferase), giving a visible signal-thus identifying the patient's viral tropism. Viral load must be at least 1,000 copies/ml to determine a patient's viral tropism.

Monogram (San Francisco, CA, USA) announced the commercial introduction of its Trofile assay following the announcement that Pfizer
(New York, NY, USA) received US Food and Drug Administration (FDA) approval of a novel HIV therapy, Selzentry (maraviroc), a CCR% antagonist. Trofile was the test used for patient selection for Selzentry's clinical development program and the two companies are engaged in a collaboration agreement to make Monogram's assay available for patient use globally.

Selzentry has been approved for the combination antiretroviral treatment of adults infected with only CCR5-tropic HIV-1 who have evidence of viral replication and have HIV-1 strains resistant to multiple antiretroviral agents. The FDA-approved label requires that tropism testing to identify patients infected with R5 virus guide the use of Selzentry.

Trofile is a vital new tool that helps physicians make the most informed treatment decisions for their patients living with HIV. Combined with Pfizer's new therapy, this represents a major milestone in the treatment of HIV, said Monogram CEO Bill Young. [The] approval also marks an important landmark in personalized medicine as the healthcare community shifts to treat patients individually by combining powerful diagnostic tools with drug therapies to better predict an individual patient's response.


Related Links:
Monogram
Pfizer

Gold Member
SARS‑CoV‑2/Flu A/Flu B/RSV Sample-To-Answer Test
SARS‑CoV‑2/Flu A/Flu B/RSV Cartridge (CE-IVD)
Radiology Monitor
MDNC-6121 Barco Nio Color 5.8MP
Digital Radiography System (Ceiling Free)
Digix CF Series
Hybrid Arch Device
Neo EDE
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Artificial Intelligence

view channel
Image: Clinical LLM Performance Improves by >300% When Provided with High-Quality Real-World Evidence in New Precision Medicine Benchmark (Photo courtesy of Atropos Health)

New Benchmark Highlights Evidence Gaps in AI Responses to Clinical Questions

Many clinical decisions still rely on limited evidence, while most artificial intelligence benchmarks overlook the patient context that shapes real-world care. General large language models can also struggle... Read more

Critical Care

view channel
Image Credit: Adobe Stock

New ECG Foundation Model Enables Broad Cardiac Diagnosis and Risk Prediction

Electrocardiograms are central to cardiovascular decision-making, but conventional artificial intelligence models are often trained for narrow tasks, such as detecting a single arrhythmia.... Read more

Point of Care

view channel
Image Credit: 123RF

Continuous Glucose Monitoring Identifies Cardiometabolic Risk in Adults Without Diabetes

Dysglycemia—abnormal blood glucose regulation—can fluctuate throughout the day and often escape conventional screening. Clinicians typically rely on fasting plasma glucose and hemoglobin A1c, which offer... Read more

Business

view channel
Image: LigaSure RAS Maryland, designed for the Valleylab FT10 platform on Hugo RAS, seals and cuts vessels, tissue, and lymphatics up to 7 mm in diameter (Photo courtesy of Medtronic)

Medtronic Receives FDA Clearance for Vessel-Sealing Instrument for Robotic Surgery

As robotic-assisted surgery expands across U.S. hospitals, teams increasingly seek energy instruments with the familiarity and performance of tools used in open and laparoscopic procedures.... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.